Our technology platform utilizes retroviral replicating vectors (RRVs), which are designed to selectively delivers therapeutic genes to, and persist within, cancer cells. Cancer cells learn how to evade the immune system and in doing so create a sanctuary for RRV infection. RRVs integrate into the DNA of dividing cancer cells, which then serve as a factory for producing additional RRVs. These new RRVs then spread to neighboring cancer cells, repeating the process and providing for a long-term presence of Tocagen’s therapeutic genes within the tumor.
Due to the novel mechanisms of action and favorable safety profile in clinical studies to date, Tocagen believes its RRV platform and lead product candidate, Toca 511 & Toca FC , have the ability to selectively infect cancer cells to stimulate robust and durable anti-cancer immune responses, and can do so with minimal toxicity.